IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells – Gordon Research Conference

LAWRENCEVILLE, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., the company’s Executive Vice President and Chief Science Officer, presented new PlaCCine preclinical data at the 2023 Viruses and Cells – Gordon Research Conference in Barcelona. Dr. Khursheed’s presentation, titled “A Novel DNA Vaccine Approach to Prophylactic and Therapeutic Vaccines,” was delivered on May 25, 2023, and described IMUNON’S PlaCCine technology platform for the development of next-generation vaccines. Dr. Anwer’s presentation is available [here].